Navigation Links
Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
Date:10/7/2011

blished and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About Amphastar Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc., established in 1996, is a specialty and generic pharmaceutical company focusing on injectable, inhalation, and other categories of pharmaceutical products. Amphastar's state-of-the-art, aseptic, cGMP compliant facilities develop, manufacture, and market innovative proprietary and generic products using new technologies and delivery systems.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... TOKYO , July 2, 2015  Konica Minolta, ... today announced that it has acquired Sawae Technologica Ltda., ... Brazil , through its Brazilian healthcare ... . Local Brazil ... increasing population exceeding 200 million, significant healthcare ...
(Date:7/2/2015)... South Korea, July 2, 2015 ALPINION MEDICAL SYSTEMS ... E-CUBE Series ultrasound system. Developed to enhance user experience ... the E-CUBE 15 EX produces superb image quality. With ... in women,s health, general imaging, and shared service applications. ... latest in the renowned E-CUBE Series, the E-CUBE 15 ...
(Date:7/2/2015)... July 2, 2015   Wilson Therapeutics AB , ... Hans Schikan to its board of directors. The appointment ... Meeting on June 30. "We are delighted ... Jonas Hansson , CEO of Wilson Therapeutics. "Hans ... we look forward to his contributions to the Company." ...
Breaking Medicine Technology:Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3Wilson Therapeutics Appoints Hans Schikan to its Board of Directors 2
... Michael Porter, Ph.D., has joined the board of ... biotechnology company focused on the discovery and development ...   http://photos.prnewswire.com/prnh/20110125/NE34069 ) Professor Porter, ... Business School, is recognized as a leading authority ...
... 2011 CardioFocus announced that two "live cases" ... The first live case was a satellite transmission ... broadcast to the 16th Annual Boston Symposium on ... the treatment of atrial fibrillation served as moderators ...
Cached Medicine Technology:Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors 2Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors 3Two Laser Balloon 'Live Cases' Shed New Light on Direct Visualization and PV Ablation 2
(Date:7/2/2015)... CA (PRWEB) , ... July 02, 2015 , ... ... procedures and executing them with care and precision. There is an art and ... has had the honor of successfully reshaping the facial features and lives of ...
(Date:7/2/2015)... ... July 02, 2015 , ... Scientists at the University ... through five federal grants to study a group of related mosquito-borne viruses. The ... , The research will be conducted in the Regional Biocontainment Laboratory (RBL) at ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Indiana ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of the Gelatin Capsule manufacturers. The report is a valuable source of guidance ... depicts the global and Chinese market for the Gelatin Capsule industry including capacity, ...
(Date:7/2/2015)... Mobile, AL (PRWEB) , ... July 02, 2015 , ... Every year, DUI arrests and ... of July may be the deadliest day of the year when it comes to being ... , “The National Highway Traffic Safety Association reports that 40% of all highway deaths between ...
Breaking Medicine News(10 mins):Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 2Health News:Dr. Kevin Sadati Featured in July Issue of Popular National Magazines 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 2Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 3Health News:Mosquito-Borne Viruses Subject of $4M in Federal Grants to Scientists in Pitt’s Center for Vaccine Research 4Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 2Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 3Health News:Gelatin Capsule Market Outlook & Forecast Report 2015-2020 4Health News:Attorney David Maloney Stresses Safety through Sobriety 2
... with depression, bipolar disorders could receive more targeted treatment ... types of imaging techniques enable researchers to map brain ... in depression, bipolar disorder and other mood disorders, and ... these techniques was expected to be presented Tuesday during ...
... to Secondhand Smoke,in the Nation,s Capitol, Statement of ... 6 On behalf of the American,Lung Association, I ... (D-OH), Dick Durbin (D-IL) and Jack Reed (D-RI) for,their ... in the,Senate. For too long, Senators, staff and visitors ...
... XM Satellite Radio announced today,the second annual ... Sam,s Club raise $10 million in May for ... and improving the,lives of children at hospitals across ... The XMKiDS Traveling Roadshow will kick-off on ...
... France, May 6 NicOx S.A.,(Euronext Paris: COX) ... 2 study,conducted by its partner Pfizer Inc, which ... PF-03187207 to Xalatan(R) (latanoprost) 0.005% in,patients with primary ... PF-03187207 demonstrated a clinically significant reduction,in diurnal intraocular ...
... into melanoma by showing the interaction of two key ... Penn State scientists also demonstrate that therapeutic targeting of ... this deadly form of cancer. , "We have shown ... communicate with one another in a mole, they cooperate ...
... Health Inc. (TSX: DAX),(Nasdaq: DRAX ) will report ... Friday May 9, 2008., Annual and Special Meeting ... "Meeting") of shareholders of,DRAXIS is scheduled to be held ... Bank Tower, Toronto, Ontario, Canada on Friday, May 23, ...
Cached Medicine News:Health News:Imaging Advances Map Brain Areas Affecting Mood 2Health News:Imaging Advances Map Brain Areas Affecting Mood 3Health News:American Lung Association Hails Decision to Snuff Out Smoking in U.S. Senate Lounges 2Health News:XM Launches Second Annual 'XMKiDS Traveling Roadshow' National Initiative Benefiting Children's Miracle Network 2Health News:XM Launches Second Annual 'XMKiDS Traveling Roadshow' National Initiative Benefiting Children's Miracle Network 3Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 2Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 3Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 4Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 5Health News:NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program 6Health News:Scientists identify interacting proteins key to melanoma development, treatment 2Health News:Scientists identify interacting proteins key to melanoma development, treatment 3Health News:DRAXIS to Report First Quarter Results on May 9th 2Health News:DRAXIS to Report First Quarter Results on May 9th 3Health News:DRAXIS to Report First Quarter Results on May 9th 4
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
... Tip flattened and angled 90 1.0mm from end, ... lock high pressure extension tubing set, Capable of ... OD- 1.5mm (.06 in) long luer lock, high ... tubing. Bend 1.0mm from end. (Cannulas ...
Rounded tip for even incisions reducing post-op astigmatism...
Stab incision blades color coded for simple and accurate identification...
Medicine Products: